Phosphodiesterase inhibitors vs placeboMigraine frequency Number of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 111 participantsLow
Phosphodiesterase inhibitors vs placeboSeverity of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 111 participantsVery low
Phosphodiesterase inhibitors vs placeboDuration of attacks · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 73 participantsLow
Phosphodiesterase inhibitors vs placeboQoL · primary Raynaud's phenomenonThe review found no eligible studies for this question.1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Phosphodiesterase inhibitors vs placeboAdverse events · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 138 participantsGRADE not reported
Phosphodiesterase inhibitors vs placeboRCS · primary Raynaud's phenomenon1 finding from 1 reviewVasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 79 participantsLow